Gujarat Terce Laboratories Ltd
Incorporated in 1985. Gujarat Terce Laboratories Ltd is engaged in development, manufacturing, marketing and distribution of medicines, healthcare products and branded generics
- Market Cap ₹ 29.6 Cr.
- Current Price ₹ 38.0
- High / Low ₹ 73.0 / 37.2
- Stock P/E
- Book Value ₹ 13.0
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 3.00% over last quarter.
Cons
- Stock is trading at 2.93 times its book value
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| 31.03 | 37.54 | 25.18 | |
| 30.54 | 36.86 | 27.95 | |
| Operating Profit | 0.49 | 0.68 | -2.77 |
| OPM % | 1.58% | 1.81% | -11.00% |
| 0.32 | 0.29 | 0.80 | |
| Interest | 0.25 | 0.29 | 0.39 |
| Depreciation | 0.21 | 0.24 | 0.18 |
| Profit before tax | 0.35 | 0.44 | -2.54 |
| Tax % | -25.71% | 36.36% | -0.39% |
| 0.43 | 0.28 | -2.52 | |
| EPS in Rs | 0.58 | 0.38 | -3.40 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1000% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 38% |
| 3 Years: | 30% |
| 1 Year: | -47% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Sep 2021 | |
|---|---|---|---|
| Equity Capital | 7.42 | 7.42 | 7.42 |
| Reserves | 3.41 | 3.69 | 2.19 |
| 0.65 | 2.38 | 4.11 | |
| 7.86 | 8.85 | 11.23 | |
| Total Liabilities | 19.34 | 22.34 | 24.95 |
| 2.06 | 2.30 | 3.53 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.29 | 0.27 | 0.28 |
| 16.99 | 19.77 | 21.14 | |
| Total Assets | 19.34 | 22.34 | 24.95 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| Debtor Days | 53.29 | 68.16 | |
| Inventory Days | 119.66 | 90.00 | |
| Days Payable | 88.95 | 83.71 | |
| Cash Conversion Cycle | 83.99 | 74.46 | |
| Working Capital Days | 27.88 | 25.18 | |
| ROCE % | 5.85% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Employee Strength Numbers ・Standalone data |
|
|||||||||
| Field Force Strength (Medical Representatives) Numbers ・Standalone data |
||||||||||
| Chemists Reached Numbers ・Standalone data |
||||||||||
| Installed Capsule Capacity Lakh Units ・Standalone data |
||||||||||
| Installed Tablet Capacity Lakh Units ・Standalone data |
||||||||||
| Medical Practitioners / Doctors Reached Numbers ・Standalone data |
||||||||||
| Stockists / Distributors Numbers ・Standalone data |
||||||||||
| PCPM (Per Candidate Per Month Productivity) INR Lacs ・Standalone data |
||||||||||
| Actual Capsule Production Lakh Units ・Standalone data |
||||||||||
| Actual Tablet Production Lakh Units ・Standalone data |
||||||||||
| Number of SKUs Numbers ・Standalone data |
||||||||||
Documents
Announcements
-
Intimation Of Trading Approval For 3,71,000 Equity Shares Of Face Value Rs. 10/- Each Allotted Pursuant To Conversion Of Warrants Issued On Preferential Basis From BSE Limited
24 Feb - Trading approval for 3,71,000 shares (Rs.27.70 premium) to Mr. Aalap Prajapati; listed effective Feb 25, 2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Feb
-
Announcement under Regulation 30 (LODR)-Investor Presentation
4 Feb - Investor Presentation for third quarter and nine months ended on 31 December 2025
- Unaudited Standalone Financial Results Of The Company For The Third Quarter And Nine Months Ended 31 December 2025, Subjected To Limited Review Of The Statutory Auditor Of The Company - Regulations 30 And 33 Of The SEBI (LODR) Regulations, 2015. 4 Feb
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 4 February 2026
4 Feb - Unaudited standalone results for Q3 and nine months ended 31 Dec 2025 approved; limited review unmodified.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Jan 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Jan 2022TranscriptAI SummaryPPT
-
Oct 2021TranscriptAI SummaryPPT
Product Profile:[1]
Company has an extensive basket of 50 Brands (125 products) with a portfolio contributing to 10 therapeutic areas, covering multiple dosage forms like Tablets, Capsules, Oral Liquids, Ointments and Injectables.